Factors Affecting Recurrent Deep Vein Thrombosis after Pharmacomechanical Thrombolysis and Left Iliac Vein Stent Placement in Patients with Iliac Vein Compression Syndrome

PurposeThis study evaluated the factors affecting contralateral and ipsilateral recurrent deep vein thrombosis (DVT) after iliac vein stent placement in patients with iliac vein compression syndrome (IVCS).Materials and MethodsData from 130 patients (95 female patients) who underwent catheter-directed thrombolysis and stent placement for IVCS with left lower leg thrombosis at a single institution were retrospectively analyzed. Mean patient age was 69.0 ± 14.0 years old. Median follow-up was 14 months (range, 3–164 months). Anticoagulation therapy was prescribed for 6 months, followed by lifelong antiplatelet therapy. Multivariate logistic regression analysis was performed to evaluate the factors affecting the development of contralateral and ipsilateral recurrent DVT.ResultsSeven patients (5.4%) developed contralateral DVT (median, 26 months; range, 2–61 months), and 11 patients (8.5%) developed ipsilateral DVT (median, 1 month; range, 0–53 months). Stent location (odds ratio [OR], 11.564; 95% confidence interval [CI], 1.159–115.417) and in-stent thrombosis during follow-up (OR, 15.142; 95% CI, 1.406–163.119) were predictors of recurrent contralateral DVT. Thrombophilia (OR, 47.560; 95% CI, 2.369–954.711), remaining inferior vena cava filter (OR, 30.552; 95% CI, 3.495–267.122), and in-stent thrombosis during follow-up (OR, 82.057; 95% CI, 2.915–2309.848) were predictors of ipsilateral DVT.ConclusionsContralateral DVT occurs late and is associated with extension of the iliac vein stent to the inferior vena cava and in-stent thrombosis. Ipsilateral DVT occurs relatively early and is associated with thrombophilia, remaining inferior vena cava filter, and in-stent thrombosis.     

CT动态增强鉴别肾上腺乏脂肪腺瘤与肾上腺结节样增生的价值

目的探讨CT动态增强对鉴别肾上腺乏脂肪腺瘤与肾上腺结节样增生的价值。方法回顾性分析经手术病理证实的12例肾上腺乏脂肪腺瘤和27例肾上腺结节样增生患者的病例资料,统计两组病例各期增强CT值,利用公式灌注值P=CT静脉期-CT平扫期、廓清值C=CT静脉期-CT延迟期、绝对廓清灌注指数APC=(C/P)×100%及相对廓清灌注指数RAPC=(C/CT静脉期)×100%得到相关参数,并通过绘制受试者工作特征曲线,鉴别两者的最佳价值。结果肾上腺乏脂肪腺瘤直径较结节样增生更大;肾上腺乏脂肪腺瘤病灶各期CT值均明显高于结节样增生,且两者灌注值P、廓清值C、APC及RAPC有明显的统计学差异。年龄、性别、高血压、病灶位置、对侧肾上腺萎缩及动脉期CT值对鉴别两者无显著意义。结论CT动态增强扫描有助于鉴别肾上腺乏脂肪腺瘤和肾上腺结节样增生。     

中老年男性下尿路症状的流行病学调查

为了了解下尿路症状在中、老年男性中的流行情况，用附加了二个症状问题的ＳＬ问卷对８７１名５２～７４岁的男子作回顾性调查，对调查结果作了年龄分组分析。结果发现：平均ＩＰＳＳ总分为４．９３分，无症状者为１２．２％，轻症者为６４．７％，中度症状者为１９．６％，重症者为３．５％。夜尿者占７２．３％，尿终滴沥占５４．４％，而症状中分值＞３分者尿终滴沥占２５．６％，夜尿占１４．６％，平均ＱＯＬ为１．７４，ＱＯＬ为０～２、３、４～６的比例分别为５２．７％、４６．０％、１．３％。ＱＯＬ与ＩＰＳＳ的相关性较好（ｒ＝０．６２），与梗阻症状群的相关性（ｒ＝０．５７）优于与刺激症状的相关性（ｒ＝０．４４）。中重度症状者中有７２．０％的人未进行治疗。     

诱导型一氧化氮合酶与移植血管平滑肌细胞增生的关系

目的　探讨诱导型一氧化氮合酶 (iNOS)与移植血管平滑肌细胞增生的关系。方法　新西兰大白兔 15只随机分成 3组 ,建立双侧颈动脉间置移植颈外静脉的动物模型。高剂量组每日喂食L 精氨酸 (L Arg) 2 5 0mg/kg ,低剂量组每日喂食L Arg 12 5mg/kg ;对照组不喂食L Arg ,持续 2周。检测血浆和组织匀浆一氧化氮(NO)水平 ,移植血管iNOSmRNA表达。观察术后 3和 6周移植血管平滑肌细胞增生。结果　 1.iNOS活性 :(1)血浆NO水平 :实验组血浆NO水平显著高于对照组 ,高剂量组血浆NO水平高于低剂量组 ;(2 )组织匀浆一氧化氮合酶 (NOS)活性 :实验组组织匀浆NOS活性显著高于对照组 ;(3)组织匀浆iNOSmRNA表达 :术后 3周实验组iNOSmRNA表达 ,对照组无表达 ;术后 6周实验组iNOSmRNA表达高于对照组 ,高剂量组高于低剂量组。 2 .移植血管平滑肌细胞形态学变化 :(1)SMA免疫组化染色 :实验组移植血管平滑肌细胞厚度低于对照组 ;术后 6周低剂量组移植血管平滑肌细胞厚度低于高剂量组 ;(2 )PCNA免疫组化染色 :术后 3周实验组平滑肌细胞增殖低于对照组 ;术后 6周低剂量组平滑肌细胞增殖低于对照组和高剂量组。结论　iNOS表达致体内NO水平增高可抑制移植血管平滑肌细胞增生 ;NO浓度与平滑肌细胞增生关系密切     

经尿道前列腺电切气化术治疗前列腺增生568例报告

目的 :进一步探讨前列腺增生 (BPH)的有效手术新方法。方法 :采用经尿道前列腺电切术和气化术治疗BPH患者 5 6 8例。结果 :疗效满意 ,术后 3～ 6个月随访 ,国际前列腺症状评分 (IPSS) 8.5± 1.5分 ;最大尿流率 (Q max) 2 0 .5± 4 .5ml s,剩余尿量 2 9.1± 14 .2ml,未出现严重并发症。结论 :将电切和气化相结合行经尿道前列腺切除术是一种安全性高、并发症少、疗效确切的新手术方法 ,具有操作易掌握、出血少、速度快、安全可靠等优点。     

Castleman disease: surgical cure in pediatric patients

Castleman disease is a rare disorder characterized by lymphoid hyperplasia which rarely manifests in children. We present 2 cases which highlight both histologic variants of this disease, and provide suggestions regarding workup and treatment with the goal of making practitioners aware of Castleman disease in the differential diagnosis of a child presenting with vague symptoms.     

Loss of heterozygosity alterations associated with progesterone therapy in endometrial hyperplasia and adenocarcinoma

Loss of heterozygosity (LOH) was analyzed in four patients with endometrial hyperplasia (EH) with atypia (two patients) and without atypia (two patients) and in five patients with endometrial adenocarcinoma (EAC) to clarify the clinicopathologic relationship between genetic alterations and hormone therapy. Each patient was initially administered high-dose medroxyprogesterone acetate (MPA) as a uterine-sparing treatment. The five microsatellite markers used to analyze LOH were at chromosomal loci 8p22.1, 8p21, 8p21.3, 8p22, and 8p22. DNA was extracted from paraffin-embedded sections before, during, and after MPA therapy using laser capture microdissection. As a result, LOH was more frequently detected after MPA therapy (overall ratios were 16, 17, and 29% before, during, and after MPA therapy, respectively). LOH is more easily detected in EH loci than in EAC loci before MPA. For EAC, initial LOH detection on chromosome 8 may be related to an incomplete response to MPA, but negative LOH does not guarantee a favorable treatment outcome. For EH or atypical endometrial hyperplasia, it is unknown whether LOH alteration associated with MPA therapy is related to atypia of the disease.     

良性前列腺增生中医证型与尿动力学参数相关性研究

目的:探讨良性前列腺增生(BPH)中医证型与尿动力学参数的相关性。方法:152例BPH患者,中医辨证分为肾阴不足、肾阳虚弱、瘀阻水道、脾气虚弱、肺热气郁、湿热下注、痰浊郁结七型,均进行尿动力学检查。结果:152例BPH患者中,肾阳虚弱型71例(46.71%),瘀阻水道型40例(26.31%),肾阴不足型14例(9.21%)。膀胱出口梗阻为III～VI度肾阳虚弱型有58例,瘀阻水道型有38例,其中严重梗阻(V～VI)26例。膀胱逼尿肌收缩功能极弱中(n=12),肾阳虚弱型4例,占33.33%(4/12),瘀阻水道型7例,占58.33%(7/12);膀胱逼尿肌收缩功能弱者中(n=48),肾阳虚弱型为27例,占56.25%(27/48),瘀阻水道型17例,占35.42%(17/48)。结论:BPH中医各辨证分型与膀胱出口梗阻和膀胱逼尿肌收缩力有一定的相关性,从而为中医证型的量化和客观化提供相应的证据。     

经尿道气化电切治疗前列腺增生

目的 探讨经尿道气化电切术(TUVP)治疗前列腺增生(BPH)的安全性和有效性.方法 对161例前列腺增生患者行TUVP治疗,其中伴全身症状和泌尿系并发症2种以上的高危患者、前列腺重量＞50g的患者共68例.平均年龄72.5岁,经围手术期处理后行TUVP治疗.结果 所有患者均安全度过围手术期.随访3～24个月,平均IPSS从26.6下降至6.6、MFR从6.2ml/s上升到18.6ml/s、PVR从376ml下降到8.9ml.结论 TUVP治疗BPH以及高危重度BPH是安全有效的,强调术中对前列腺尖部采用电切治疗以避免术后尿失禁等并发症的发生.